Cargando…

The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis

INTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic and systemic inflammation. Besides, it is known that RA patients may present several comorbidities, such as sarcopenia, a condition where patients present both muscle mass and muscle quality impairment. RA tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hein, Thales R., Peterson, Leonardo, Bartikoski, Barbara J., Portes, Juliana, Espírito Santo, Rafaela C., Xavier, Ricardo M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295282/ https://www.ncbi.nlm.nih.gov/pubmed/35854372 http://dx.doi.org/10.1186/s13075-022-02858-y

Ejemplares similares

Response to Comment on “The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis”
por: Hein, Thales R., et al.
Publicado: (2022)

A Review of Metabolomic Profiling in Rheumatoid Arthritis: Bringing New Insights in Disease Pathogenesis, Treatment and Comorbidities
por: Bartikoski, Bárbara Jonson, et al.
Publicado: (2022)

The effects of resistance training with blood flow restriction on muscle strength, muscle hypertrophy and functionality in patients with osteoarthritis and rheumatoid arthritis: A systematic review with meta-analysis
por: dos Santos, Leonardo Peterson, et al.
Publicado: (2021)

Funcionality assessed by the core set of the international classification of functionality and health for rheumatoid arthritis: A cohort study
por: Portes, Juliana, et al.
Publicado: (2023)

Changes in physical function over time in rheumatoid arthritis patients: A cohort study
por: Santo, Rafaela Cavalheiro do Espírito, et al.
Publicado: (2023)

Urinary metabolomic biomarker candidates for skeletal muscle wasting in patients with rheumatoid arthritis
por: Oliveira, Marianne S., et al.
Publicado: (2023)

Comment on “The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis”
por: Minamino, Hiroto, et al.
Publicado: (2022)

Morphological Parameters in Quadriceps Muscle Were Associated with Clinical Features and Muscle Strength of Women with Rheumatoid Arthritis: A Cross-Sectional Study
por: dos Santos, Leonardo Peterson, et al.
Publicado: (2021)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta‐analysis
por: Santo, Rafaela C.E., et al.
Publicado: (2018)

A Treatise on Rheumatism and Rheumatoid Arthritis
Publicado: (1892)

Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
por: Arias de la Rosa, Iván, et al.
Publicado: (2021)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Cataphoresis in the Treatment of Gout, Rheumatism, and Rheumatoid Arthritis
por: Begg, Charles
Publicado: (1902)

The Differential Diagnosis of Gout, Rheumatism, and Rheumatoid Arthritis
por: Luff, Arthur P.
Publicado: (1900)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Skeletal muscle redox signaling in rheumatoid arthritis
por: Steinz, Maarten M., et al.
Publicado: (2020)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
por: Heidari, Behzad, et al.
Publicado: (2012)

Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
por: Khalid, Sabeen, et al.
Publicado: (2019)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis
por: Si, Lulu, et al.
Publicado: (2022)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Collagen‐induced arthritis as an animal model of rheumatoid cachexia
por: Alabarse, Paulo V.G., et al.
Publicado: (2018)

A COMPARATIVE STUDY OF SUBCUTANEOUS NODULES IN RHEUMATIC FEVER AND RHEUMATOID ARTHRITIS
por: Dawson, M. H.
Publicado: (1933)

The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
por: Chou, CT, et al.
Publicado: (2007)

Periodontal Condition in Patients with Rheumatoid Arthritis: Effect of Anti-rheumatic Drugs
por: Kordtabar, Samira, et al.
Publicado: (2019)

Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients
por: de Smit, Menke J., et al.
Publicado: (2021)

Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
por: Baoqi, Yang, et al.
Publicado: (2022)

Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region
por: Machado, Daniel A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hr64h7hn2gm0tjd95f1v83der5